TEXT-EXTRACT 2 filename2.txt United States securities and exchange commission logo January 2, 2024 Mark Ragosa Senior Vice President and Chief Financial Officer Kiniksa Pharmaceuticals, Ltd. Clarendon House 2 Church Street Hamilton HM11, Bermuda Re: Kiniksa Pharmaceuticals, Ltd. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed March 2, 2023 File No. 001-38492 Dear Mark Ragosa: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Maddy Zeylikman